Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2006-09-05 | Reverse | 1:10 |
| 2006-08-01 | Forward | 25:4 |
| 1996-10-22 | Forward | 3:2 |
| 1995-07-03 | Forward | 3:2 |
| 1993-05-03 | Forward | 3:2 |
| 1992-07-06 | Forward | 3:2 |
| 1991-03-01 | Forward | 3:2 |
| 1986-07-21 | Forward | 3:2 |
| 1985-03-19 | Forward | 3:2 |
Avis Budget Group, Inc. provides global car and truck rentals, car sharing, and mobility services through brands like Avis, Budget, and Zipcar, serving consumers and businesses across approximately 10,400 locations worldwide.
A premium car rental service offering first-class experiences with curbside pickup, dedicated concierge, and access to current-model vehicles, eliminating common inconveniences like counters and shuttles.
Avis Budget Group was hit with a class-action lawsuit on May 5, 2025, alleging the company misled investors by failing to disclose a plan to accelerate its vehicle fleet rotation. This strategic shift resulted in a massive $2.3 billion non-cash impairment charge and a reported net loss of $1.96 billion for Q4 2024, causing a significant drop in the company's stock price upon disclosure.
Avis Budget Group announced a multi-year strategic partnership with Waymo to launch and scale a fully autonomous ride-hailing service, starting in Dallas. This move positions Avis as a key operational partner in the growing autonomous vehicle ecosystem, leveraging its expertise in fleet management for a new mobility frontier.
Beaten-down rental stocks are bouncing while the wider transportation sector slips, and Hertz Global Holdings (NASDAQ:HTZ) is leading the rebound from the deepest hole in the group. Hertz stock is at $2.
First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.
CAR's stronger utilization and lower fleet costs lift second-quarter profits despite fewer vehicles and softer rental volumes.
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma.
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 URI | $1034.36 | COMPARE |
 AER | $142.68 | COMPARE |
 UHAL | $59.65 | COMPARE |
 R | $232.48 | COMPARE |
 ENS | $193.47 | COMPARE |
 GATX | $163.91 | COMPARE |
 OMAB | $95.53 | COMPARE |
 IEP | $6.63 | COMPARE |
